CSL (CSLLY) AI Stock Analysis

• Market Cap: $67.42B
• Dividend Yield: 1.92%
• Average Volume (3M): 11.01K
• Price to Earnings (P/E): 22.5
• Beta (1Y): 0.49
• Revenue Growth: 5.08%
• EPS Growth: 13.41%
• Country: US
• Employees: 32,698
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): 1.03
• Shares Outstanding: 968,424,260
• 10 Day Avg. Volume: 24,135
• 30 Day Avg. Volume: 11,011
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 5.86
• Enterprise Value/Gross Profit: 11.93
• Enterprise Value/Ebitda: 17.63
• 1Y Price Target: $99.00
• Price Target Upside: 42.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: $99.00 ▲(42.10% Upside)

CSL's strong financial performance and positive earnings guidance are key strengths, supporting a solid stock score. Technical indicators suggest caution due to overbought conditions, while valuation remains a concern with a high P/E ratio. Overall, the company's growth prospects and financial stability are well-regarded, though attention to competitive pressures and leverage is advised.

CSL Business Overview & Revenue Model

Company Description

CSL Limited (CSLLY) is a global biotechnology company that specializes in the development and manufacture of innovative biotherapies and influenza vaccines. It operates through two main segments: CSL Behring and Seqirus. CSL Behring focuses on providing life-saving treatments for people with rare and serious diseases through its plasma-derived therapies, recombinant therapies, and related products. Seqirus, on the other hand, is one of the largest influenza vaccine companies in the world, supplying vaccines to both public and private sectors globally.

How the Company Makes Money

CSL Limited generates revenue primarily through the sale of its biotherapeutic and vaccine products. Its major revenue streams include plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors that treat conditions like hemophilia and immune deficiencies. Additionally, its Seqirus segment contributes significantly to revenue through the production and distribution of influenza vaccines. The company benefits from strategic partnerships and collaborations that enhance its research and development capabilities, allowing it to innovate and expand its product offerings. CSL's earnings are also influenced by its extensive global distribution network and its ability to leverage economies of scale in manufacturing.

CSL Financial Statement Overview

Summary

CSL showcases strong financial health with significant revenue growth and stable profitability. The balance sheet is sound with a robust equity base, though leverage remains a concern. Cash flow generation is healthy, supporting future investments. Overall, CSL's financial stability and growth trajectory are solid.

Income Statement

CSL has demonstrated strong revenue growth with a remarkable increase from $5.95B in 2019 to $14.69B in 2024. The gross profit margin has consistently been healthy, maintaining above 50% over the years, while the net profit margin has shown resilience, peaking at 18% in the most recent year. EBIT and EBITDA margins indicate solid operational efficiency. The company's ability to grow revenues and maintain stable margins underscores its competitive positioning in the biotechnology industry.

Balance Sheet

The balance sheet reflects a robust equity base with stockholders' equity increasing considerably to $17.33B. The debt-to-equity ratio is manageable, though leverage has increased, which may pose some financial risks if earnings do not continue to grow. The equity ratio has shown stability, supporting the company's capacity to leverage its assets effectively. Overall, CSL's balance sheet is strong but could benefit from reduced leverage.

Cash Flow

CSL's cash flow statement reveals a healthy operating cash flow, consistently growing over the years. The free cash flow has also increased, indicating effective capital expenditure management. The operating cash flow to net income ratio suggests that cash generation is well-aligned with reported earnings, improving financial stability. The company is in a solid cash position to support its growth initiatives.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	14.69B	13.17B	10.49B	10.33B	9.41B
Gross Profit	7.56B	9.47B	5.66B	5.74B	5.28B
EBITDA	4.73B	3.90B	3.46B	2.72B	2.18B
Net Income	2.64B	2.19B	3.11B	2.39B	2.17B
Balance Sheet
Total Assets	38.02B	54.43B	41.22B	18.16B	15.46B
Cash, Cash Equivalents and Short-Term Investments	1.66B	2.33B	15.18B	1.81B	1.19B
Total Debt	12.18B	18.37B	14.04B	5.81B	5.99B
Total Liabilities	18.62B	27.65B	20.02B	9.74B	8.94B
Stockholders Equity	17.33B	23.72B	21.20B	8.38B	6.53B
Cash Flow
Free Cash Flow	1.51B	1.35B	1.90B	1.97B	1.16B
Operating Cash Flow	2.76B	3.87B	3.62B	3.65B	2.57B
Investing Cash Flow	-1.26B	-17.61B	-2.26B	-1.68B	-1.41B
Financing Cash Flow	-1.28B	677.92M	10.58B	-1.41B	-664.30M

CSL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 69.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Negative. The current price of 69.67 is below the 20-day moving average (MA) of 79.56, below the 50-day MA of 80.96, and below the 200-day MA of 82.10, indicating a bearish trend. The MACD of -4.04 indicates Positive momentum. The RSI at 26.94 is Positive, neither overbought nor oversold. The STOCH value of 2.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSLLY.

CSL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSLLY	77 Outperform	$67.42B	22.50	16.36%	1.92%	5.08%	13.41%
VRTX	75 Outperform	$100.25B	27.95	22.77%	―	10.38%	―
ARGX	74 Outperform	$43.19B	33.46	24.75%	―	89.58%	―
REGN	72 Outperform	$61.55B	14.63	15.34%	0.45%	5.38%	3.58%
ALNY	60 Neutral	$58.53B	―	-257.82%	―	5.01%	-330.09%
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
BNTX	49 Neutral	$24.04B	―	-1.81%	―	7.51%	30.53%